Table 2.
CYP2C8 genotype frequencies by treatment outcome after treatment with artesunate–amodiaquine
| Treatment outcome | *1/*1 | *2 carriers | *3 carriers | Total |
|---|---|---|---|---|
| ACPR; % (n) | 63.3 (124) | 31.1 (61) | 5.6 (11) | 100 (196) |
| Recurrent infections; % (n) | 56.4 (75) | 38.4 (51) | 5.3 (7) | 100 (133) |
| Re-infections; % (n) | 55.9 (52) | 37.6 (35) | 6.5 (6) | 100 (93) |
| Recrudescences; % (n) | 51.7 (15) | 44.8 (13) | 3.5 (1) | 100 (29) |
| Recurrent infections IA; % (n) | 72.7 (8) | 27.3 (3) | 0.0 (0) | 100 (11) |
Relative (%) and absolute (n) genotype frequencies by treatment outcome among children under 5 years old with uncomplicated falciparum malaria in Zanzibar
ACPR adequate clinical and parasitological response, IA Inconclusive analysis